AR101185A1 - ANTI-FACTOR V OR FACTOR V ACTIVATED ANTIBODIES - Google Patents

ANTI-FACTOR V OR FACTOR V ACTIVATED ANTIBODIES

Info

Publication number
AR101185A1
AR101185A1 ARP150102212A ARP150102212A AR101185A1 AR 101185 A1 AR101185 A1 AR 101185A1 AR P150102212 A ARP150102212 A AR P150102212A AR P150102212 A ARP150102212 A AR P150102212A AR 101185 A1 AR101185 A1 AR 101185A1
Authority
AR
Argentina
Prior art keywords
seq
factor
fva
variable regions
activated antibodies
Prior art date
Application number
ARP150102212A
Other languages
Spanish (es)
Original Assignee
Novo Nordiks As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordiks As filed Critical Novo Nordiks As
Publication of AR101185A1 publication Critical patent/AR101185A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente solicitud se relaciona con anticuerpos monoclonales o fragmentos de estos, que específicamente se unen al Factor V activado (FVa), que despliegan un efecto pro-coagulante y usos terapéuticos de estos. Reivindicación 10: Un anticuerpo monoclonal anti-FVa o un fragmento de este de unión al antígeno, donde las CDR de las regiones variables de cadena ligera y pesada son como en las regiones variables definidas por la SEQ ID Nº 1 y SEQ ID Nº 2, SEQ ID Nº 3 y SEQ ID Nº 4, SEQ ID Nº 5 y SEQ ID Nº 6, SEQ ID Nº 7 y SEQ ID Nº 8, SEQ ID Nº 9 y SEQ ID Nº 10, SEQ ID Nº 11 y SEQ ID Nº 12, SEQ ID Nº 13 y SEQ ID Nº 14, SEQ ID Nº 15 y SEQ ID Nº 16, SEQ ID Nº 17 y SEQ ID Nº 18, SEQ ID Nº 19 y SEQ ID Nº 20, SEQ ID Nº 21 y SEQ ID Nº 22, SEQ ID Nº 23 y SEQ ID Nº 24, SEQ ID Nº 25 y SEQ ID Nº 26, SEQ ID Nº 27 y SEQ ID Nº 28, SEQ ID Nº 29 y SEQ ID Nº 30, SEQ ID Nº 31 y SEQ ID Nº 32, SEQ ID Nº 33 y SEQ ID Nº 34, SEQ ID Nº 39 y SEQ ID Nº 40, SEQ ID Nº 41 y SEQ ID Nº 42, SEQ ID Nº 43 y SEQ ID Nº 44.The present application relates to monoclonal antibodies or fragments thereof, which specifically bind to activated Factor V (FVa), which display a pro-coagulant effect and therapeutic uses thereof. Claim 10: An anti-FVa monoclonal antibody or an antigen-binding fragment thereof, wherein the CDRs of the light and heavy chain variable regions are as in the variable regions defined by SEQ ID No. 1 and SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6, SEQ ID No. 7 and SEQ ID No. 8, SEQ ID No. 9 and SEQ ID No. 10, SEQ ID No. 11 and SEQ ID No. 12, SEQ ID No. 13 and SEQ ID No. 14, SEQ ID No. 15 and SEQ ID No. 16, SEQ ID No. 17 and SEQ ID No. 18, SEQ ID No. 19 and SEQ ID No. 20, SEQ ID No. 21 and SEQ ID No. 22, SEQ ID No. 23 and SEQ ID No. 24, SEQ ID No. 25 and SEQ ID No. 26, SEQ ID No. 27 and SEQ ID No. 28, SEQ ID No. 29 and SEQ ID No. 30, SEQ ID No. 31 and SEQ ID No. 32, SEQ ID No. 33 and SEQ ID No. 34, SEQ ID No. 39 and SEQ ID No. 40, SEQ ID No. 41 and SEQ ID No. 42, SEQ ID No. 43 and SEQ ID No. 44.

ARP150102212A 2014-07-11 2015-07-10 ANTI-FACTOR V OR FACTOR V ACTIVATED ANTIBODIES AR101185A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14176717 2014-07-11

Publications (1)

Publication Number Publication Date
AR101185A1 true AR101185A1 (en) 2016-11-30

Family

ID=51162604

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102212A AR101185A1 (en) 2014-07-11 2015-07-10 ANTI-FACTOR V OR FACTOR V ACTIVATED ANTIBODIES

Country Status (3)

Country Link
AR (1) AR101185A1 (en)
TW (1) TW201617371A (en)
WO (1) WO2016005564A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3691673A4 (en) * 2017-10-05 2021-06-09 Epivax, Inc. Regulatory t cell epitopes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69523179T2 (en) * 1994-02-14 2002-06-06 Univ Leiden METHOD FOR DETECTING A GENETIC DEFECT ASSOCIATED WITH THROMBOSE AND / OR DEFECTIVE ANTICOAGULANCE REACTION TO ACTIVATED PROTEIN C
US20060014934A1 (en) * 2004-05-18 2006-01-19 Everse Stephen J Crystal structure of factor Vai and method for identifying blood factor Va modulators
EP1986681A4 (en) * 2006-02-23 2010-08-04 Philadelphia Children Hospital Compositions and methods for modulating hemostasis using variant forms of activated factor v
US20100322921A1 (en) * 2006-10-16 2010-12-23 Rekha Bansal METHOD OF INHIBITING COAGULATION ACTIVATION WITH HUMAN ANTI-FACTOR Va ANTIBODIES AND USE THEREOF

Also Published As

Publication number Publication date
WO2016005564A2 (en) 2016-01-14
WO2016005564A3 (en) 2016-04-07
TW201617371A (en) 2016-05-16

Similar Documents

Publication Publication Date Title
EA201791961A1 (en) ANTIBODIES SPECIFIC TO CD47 AND PD-L1
UY36194A (en) HUMANIZED ANTI-TAU ANTIBODIES
PE20190737A1 (en) ANTI-CD27 ANTIBODIES
NI201700018A (en) ANTI-LAG3 ANTIBODIES AND ANTIGEN BINDING FRAGMENTS
EA201690167A1 (en) HUMANIZED OR CHEMICAL ANTIBODIES TO CD3
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
PE20151289A1 (en) ANTIBODIES THAT JOIN THE TL1A AND ITS USES
EA201792589A1 (en) ANTIBODIES AGAINST CD123 AND CONJUGATES OF INDICATED ANTIBODIES
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
EA201890305A1 (en) HUMANIZED OR CHIMERIC CD3 ANTIBODIES
AR102239A1 (en) ANTI-OX40 HUMANIZED ANTIBODIES AND THEIR USES
CR20190009A (en) ANTI-BODIES ANTI-PD-1, A PRODUCTION METHOD AND A METHOD FOR USE.
MX353278B (en) Common light chain mouse.
PE20160690A1 (en) HUMANIZED ANTI-CD134 (OX40) ANTIBODIES AND USES OF THEM
CO2019013669A2 (en) Anti-garp-tgf-β antibodies
EA201791527A1 (en) BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII
AR105267A1 (en) TAU JOINT ANTIBODIES
EA201600276A1 (en) ANTI-IL-17-ANTIBODIES, METHOD OF THEIR RECEIVING AND METHOD OF APPLICATION
EA201992091A1 (en) ANTI-C5 ANTIBODIES AND THEIR APPLICATION
AR108717A1 (en) ANTI-BODY COAGULATION ANTIBODIES XI
EA201990894A9 (en) ANTI-PD-1 / ANTI-HER2 HETERODIMERIC BASPECIFIC ANTIBODY WITH NATURAL ANTIBODY STRUCTURE AND METHOD FOR ITS PRODUCTION
CO2017004753A2 (en) Antibodies that bind to ccr6
EA201890340A1 (en) MONOCLONAL ANTIBODY-INHIBITOR OF FACTOR XIIA
CO2019007686A2 (en) Monovalent anti-properdin antibodies and antibody fragments

Legal Events

Date Code Title Description
FB Suspension of granting procedure